作者
Yasuji Arase, Yusuke Kawamura, Yuya Seko, Mariko Kobayashi, Fumitaka Suzuki, Yoshiyuki Suzuki, Norio Akuta, Masahiro Kobayashi, Hitomi Sezaki, Satoshi Saito, Tetsuya Hosaka, Kenji Ikeda, Hiromitsu Kumada, Yuki Ohmoto‐Sekine, Shiun Dong Hsieh, Kazuhisa Amakawa, Kyoko Ogawa, Naoki Matsumoto, Akiko Iwao, Hiroshi Tsuji, Shigeko Hara, Yasumichi Mori, Minoru Okubo, Hirohito Sone, Tetsuro Kobayashi
发表日期
2013/11
期刊
Hepatology Research
卷号
43
期号
11
页码范围
1163-1168
简介
Aim
The aim of this case–control study was to assess the efficacy and safety of dipeptidyl peptidase‐4 inhibitor (sitagliptin) for type 2 diabetes mellitus (T2DM) with non‐alcoholic fatty liver disease (NAFLD).
Methods
Twenty NAFLD patients with T2DM treated by sitagliptin were retrospectively enrolled as the sitagliptin group. These patients were given sitagliptin between January 2010 and July 2011. Another 20 NAFLD patients with T2DM treated only with diet and exercise for 48 weeks were selected as the control group. Serum levels of fasting plasma glucose (FPG), hemoglobin A1C (HbA1c), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured before and 12, 24, 36 and 48 weeks after the initiation of treatment.
Results
In the sitagliptin group, average HbA1c levels decreased approximately 0.7% at 48 weeks after the initiation of sitagliptin. Next, average FPG levels …
学术搜索中的文章
Y Arase, Y Kawamura, Y Seko, M Kobayashi, F Suzuki… - Hepatology Research, 2013